# Undetectable MRD (uMRD / MRD-negative)

Source: https://onco.cc/terms/umrd/  
OnCo record `umrd` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The test for leftover cancer cells found none, down to the sensitivity of the assay (often one cell in 100,000 or a million). It is the deepest remission we can measure and is becoming a treatment goal and trial endpoint in blood cancers.

## Summary

In CLL, undetectable MRD at the end of fixed-duration venetoclax therapy predicts years off treatment and defines when to stop; in myeloma, MRD negativity at 10^-5 or 10^-6 (by next-generation flow or sequencing) is accepted by the FDA as an early endpoint for accelerated approval and guides de-escalation trials; in ALL, converting MRD-positive to negative with blinatumomab (BLAST) was the basis of its approval; in AML, NPM1 or flow MRD decides who needs transplant. MRD-positive after therapy predicts relapse and triggers intensification. The depth (10^-4 versus 10^-6) matters and assays are not interchangeable.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: uMRD; MRD-negative; MRD negative; MRD negativity rate; MRD-positive; MRD positive; MRD-persistent; MRD persistence; MRD-guided; MRD-driven; MRD-adapted; sustained MRD negativity; uMRD4; MRD 10^-5; MRD 10-6

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Minimal_residual_disease
- Wikipedia: https://en.wikipedia.org/wiki/Minimal_residual_disease

## Connected records

- terms: [Allogeneic stem cell transplant (allo-SCT)](https://onco.cc/terms/allogeneic-transplant/), [Complete response (CR) and partial response (PR)](https://onco.cc/terms/complete-response-term/), [De-escalation, escalation and response-adapted therapy](https://onco.cc/terms/de-escalation/), [Fixed-duration vs continuous therapy](https://onco.cc/terms/fixed-duration/), [Flow cytometry (immunophenotyping)](https://onco.cc/terms/flow-cytometry/), [M-protein, immunofixation and serum free light chains](https://onco.cc/terms/m-protein-free-light-chains/), [Maintenance therapy](https://onco.cc/terms/maintenance-therapy/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [Molecular response (MMR, MR4, treatment-free remission)](https://onco.cc/terms/molecular-response/), [VRd and Dara-VRd (myeloma induction regimens)](https://onco.cc/terms/vrd/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Chronic lymphocytic leukaemia, first treatment](https://onco.cc/cancers/cll-treatment-naive/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory chronic lymphocytic leukaemia](https://onco.cc/cancers/cll-relapsed/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [Blinatumomab](https://onco.cc/drugs/blinatumomab/), [clonoSEQ](https://onco.cc/drugs/clonoseq/), [Venetoclax](https://onco.cc/drugs/venetoclax/)

---
JSON: https://onco.cc/api/v1/entities/umrd.json